Fused pyrimidine derivatives as A2A / A2B inhibitors
US11168089B2 · kind B2 · utility
5Cited by
40References
36Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 17, 2019 |
| Grant date | Nov 9, 2021 |
| Priority date | — |
| Expiry date | May 17, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.